Table 2.

Association between prostate cancer risk and 13 SNPs across six vitamin D pathway genes

ReferentCodominant modelDominant model
Case/controlCase/controlCase/control
GeneSNPLocationGenotypeN/NGenotypeN/NOR (95% CI)GenotypeN/NOR (95% CI)PtrendGenotypeN/NOR (95% CI)
VDRrs3782905IVS4+6584C>GGG343/705REFCG328/5681.19 (0.99–1.43)CC89/1401.31 (0.97–1.76)0.03CG+CC417/7081.21 (1.02–1.45)
VDRrs4334089IVS2+7605G>AGG440/766REFAG290/5620.90 (0.75–1.08)AA44/1150.66 (0.46–0.96)0.03AG+AA334/6770.86 (0.72–1.02)
VDRrs7299460IVS1+2470C>TCC400/705REFCT318/5850.96 (0.80–1.15)TT58/1540.66 (0.48–0.92)0.04CT+TT376/7390.90 (0.75–1.07)
VDRrs7132324-34412C>TCC316/651REFCT355/6181.18 (0.98–1.43)TT105/1741.24 (0.94–1.63)0.06CT+TT460/7921.19 (1.00–1.43)
VDRrs7970314-35277A>GAA508/864REFAG221/4780.79 (0.65–0.95)GG34/830.69 (0.45–1.04)5.3E-03AG+GG255/5610.77 (0.64–0.93)
VDRrs7305180a-42038G>TGG559/969REFGT195/4180.81 (0.66–0.99)TT22/550.69 (0.41–1.14)0.01GT+TT217/4730.79 (0.65–0.96)
VDRrs10459217a-43364C>TTT523/885REFCT221/4680.80 (0.66–0.97)CC24/700.58 (0.36–0.93)2.5E-03CT+CC245/5380.77 (0.64–0.93)
RXRArs6537944aIVS5–694T>CTT629/1197REFCT118/1901.19 (0.92–1.52)CC11/92.35 (0.97–5.71)0.04CT+CC129/1991.24 (0.97–1.58)
RXRBrs421446-6529G>AAA353/708REFAG320/5541.16 (0.96–1.40)GG62/931.34 (0.95–1.89)0.05AG+GG382/6471.18 (0.99–1.42)
CYP24A1rs2426498a-6562G>CCC575/1108REFCG178/3171.08 (0.88–1.34)GG23/192.32 (1.26–4.30)0.04CG+GG201/3361.15 (0.94–1.41)
CYP27A1rs645163a*2503T>CCC581/996REFCT177/4200.72 (0.59–0.89)TT18/271.14 (0.62–2.09)0.02CT+TT195/4470.75 (0.61–0.91)
CYP27A1rs6436094Ex14+203A>GAA453/759REFAG254/5260.81 (0.67–0.98)GG45/920.82 (0.56–1.19)0.04AG+GG299/6180.81 (0.68–0.97)
MED16rs1651896*2265C>TCC383/647REFCT304/6070.85 (0.70–1.02)TT63/1360.78 (0.56–1.08)0.04CT+TT367/7430.83 (0.70–1.00)

NOTE: Adjusted for age and state.

Abbreviation: REF, reference.

  • aHomozygous rare allele frequency less than 5% among the controls.